https://www.chemical.ai/blog daily 0.75 2026-06-16 https://www.chemical.ai/blog/room-temperature-phosphorescence-in-amorphous-films-and-how-to-actually-make-it monthly 0.5 2026-06-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5531d2dc-cc07-4ad6-a4c9-a891b4e2e6bb/Screenshot+2026-06-16+at+1.27.47%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Figure 1. The three traditional approaches to organic phosphorescence - and why amorphous neat films have always been the hardest. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/002a779e-a0fc-4993-a427-e1fe9d773c17/Screenshot+2026-06-16+at+1.31.42%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Figure 2. How increasing intramolecular steric bulk - from mDTMe to pDTTCz - progressively enables through-space charge transfer and suppresses nonradiative decay. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7d79ff49-4df6-4446-94c6-71e0383fe275/Screenshot+2026-06-16+at+1.34.51%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/748ecd00-3c1c-4e60-8dbb-041fcaded783/Screenshot+2026-06-16+at+2.05.31%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Figure 3. RTP lifetime comparison across all four compounds - neat amorphous film (blue) vs. PMMA polymer host (green). Notably, pDTCz and pDTTCz neat films perform almost as well as the polymer host, confirming the intramolecular mechanism is doing the work. Data: Dou et al. 2024. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b3e76282-926b-4881-b244-9fcd3e3d2720/Screenshot+2026-06-16+at+1.38.46%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Figure 4. Modular assembly of pDTTCz (Target Compound) via a series of Suzuki–Miyaura, Buchwald–Hartwig, and Ullmann–Goldberg Couplings https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7155430a-0094-48ac-b88b-5cb5554b4ae2/Screenshot+2026-06-16+at+1.41.41%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Figure 5. A convergent route to pDTTCz (Target Compound) relying on a double Suzuki cross-coupling reaction in the final step https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/68f90507-e171-4593-91bf-d6ea5c883288/Screenshot+2026-06-16+at+2.04.46%E2%80%AFPM.png Blog - Room-Temperature Phosphorescence in Amorphous Films - and How to Actually Make It - Make it stand out Figure 6. Time-dependent afterglow patterns: each compound fades at a different rate after UV excitation is removed, enabling time-encoded anti-counterfeiting and data security applications. Adapted from Dou et al. (2024), Fig. 6. https://www.chemical.ai/blog/8-mainstream-synthetic-accessibility-prediction-models-a-technical-comparisonnbsp monthly 0.5 2026-05-27 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/39eb3b29-0d1c-4f46-8079-bbf793c20a40/Screenshot+2026-05-25+at+4.11.43%E2%80%AFPM.png Blog - 8 Mainstream Synthetic Accessibility Prediction Models: A Technical Comparison  - Make it stand out Figure 1: Pearson correlation between model predictions and ground truth synthesis steps https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0a9063f8-984c-4fa3-b4cf-ac51ea035a7e/Screenshot+2026-05-26+at+8.08.36%E2%80%AFPM.png Blog - 8 Mainstream Synthetic Accessibility Prediction Models: A Technical Comparison  - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b54e8013-3956-4fc9-944d-b225b282754f/Screenshot+2026-05-26+at+8.12.41%E2%80%AFPM.png Blog - 8 Mainstream Synthetic Accessibility Prediction Models: A Technical Comparison  - Make it stand out Figure 2: Prediction precision change across the top 10% of test set molecules https://www.chemical.ai/blog/chemairs-impurity-prediction monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3ea56f09-c36b-4f5c-8c16-2531a4be2ef2/Screenshot+2026-04-21+at+10.10.18%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/39f86eb3-baf7-4606-b557-12862df44501/Screenshot+2026-04-21+at+10.15.25%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 1. Partial retrosynthetic analysis of fostemsavir (1) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0471acb0-db23-438a-b67c-66eeb004a9fe/Screenshot+2026-04-21+at+10.15.50%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 2. Process impurity profile for the synthesis of potassium salt 2a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/111b9fda-37c3-4a80-b952-c120f2a8be3c/Screenshot+2026-04-21+at+11.50.37%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 3. Selected results from the ChemAIRS Impurity Prediction analysis of C–N coupling in the synthesis of fostemsavir https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/efe7d5b4-b214-46cb-9b83-4185397e95b0/Screenshot+2026-04-21+at+10.30.11%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 4. General scheme for reduction of nitroaryl 12 to aniline 13 and elaboration to vismodegib (11) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cc1f48d9-11af-4a88-b579-4074c942fb1b/Screenshot+2026-04-21+at+10.30.22%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 5. Impurities generated by reduction of nitroaryl 12 under different conditions https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/20a42a2c-fc67-436b-8dac-819a16cadec4/Screenshot+2026-04-21+at+10.23.26%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 6. Input for analysis of the nitroaryl reduction using the ChemAIRS Impurity Prediction tool https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/958b31cf-4402-4db0-afac-8ad635d3f31f/Screenshot+2026-04-21+at+10.23.35%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Figure 7. Selected results from ChemAIRS Impurity Prediction analysis of nitroaryl reduction https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/05603a87-acb3-4fe1-83ec-e8066c146430/Screenshot+2026-04-21+at+10.35.33%E2%80%AFAM.png Blog - Anticipating the Unexpected: How ChemAIRS Turns Impurity Surprises into a Thing of the Past - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/exploring-synthetic-pathways-for-deep-blue-oled-emitters-using-chemairs monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2e488c3e-6898-4cb5-be91-0f0e9f0b8ad1/Screenshot+2026-02-09+at+11.23.08%E2%80%AFPM.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Figure 1. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1cffbd3b-5e54-41bd-829a-f67266779fdd/Screenshot+2026-02-02+at+13.26.58.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Route 1. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d1872e78-b25d-449d-b3d0-1b43a5f5f62d/Screenshot+2026-02-02+at+13.27.09.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Route 2. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/23ac0450-9261-40b9-8e2d-98f7374508ce/Screenshot+2026-02-02+at+13.27.18.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Route 3. https://www.chemical.ai/blog/cortevas-new-insecticide-receives-iso-name-a-new-member-joins-the-agrochemical-industry monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8917714b-8746-4915-9c36-259274161c1a/Screenshot+2026-01-14+at+20.49.06.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/be750243-8bf1-47af-bb42-6a37d467e75c/Screenshot+2026-01-14+at+20.52.34.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1a3ef045-7b00-4e07-9f7a-8e0e8ffaa693/Screenshot+2026-01-14+at+20.55.09.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b58cf778-d0bc-42f1-8247-a2cacb540d0f/Screenshot+2026-01-14+at+20.57.10.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/empowering-radical-cross-coupling-chemistry-through-ai-driven-retrosynthesis-and-real-world-validation monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f0768d4b-c7e9-47f4-82c5-17c21c3d0d43/Screenshot+2025-11-26+at+11.23.20.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 1. Conventional Polar Cross-Coupling versus Radical Cross-Coupling Approaches https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/446385ba-cb95-48c4-8b9f-c855e6e8586c/Screenshot+2025-11-30+at+15.26.56.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7542ff32-1482-4852-910e-65dfcf0617a6/Screenshot+2025-11-30+at+15.28.25.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 2. Case study 1: Canonical cross-coupling https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6405c869-e1f3-470f-83d3-430570d5e087/Screenshot+2025-11-30+at+16.00.28.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/203ecc4f-7059-4449-a1d5-5079f51199ca/Screenshot+2025-11-30+at+16.02.56.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/acc53937-649d-42a8-ad41-2b7ba8ee2b80/Screenshot+2025-11-30+at+16.04.01.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 4. RCC Exploration Without Precedent https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7d12aa6d-d9d3-4c64-87c2-b8bd1708c264/Screenshot+2025-11-30+at+16.06.30.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 5. Three ways to drive RCC. https://www.chemical.ai/blog/dl7xc1h1477b1hp21ajpef87z13c73 monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/749baa52-a83f-4467-ab97-a4cd5ebabc00/Screenshot+2025-10-14+at+23.41.48.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 1. Crystal Structure of BCL-2 with venetoclax (PDB: 6O0K). Chemical structure of Surzetoclax (ABBV-453), a next-generation BCL-2 inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8b1deea-a640-4d7c-8241-d4d58a51521f/Screenshot+2025-10-14+at+23.48.33.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 2. Chemical structures of commonly used BCL-2 inhibitors. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1ff90b87-d379-4888-bb85-3a22e4cf2f25/Screenshot+2025-10-14+at+23.54.34.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 3. Surzetoclax’s structure: key elements https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0ec0a442-98a9-4764-be7d-12270420f21d/Screenshot+2025-10-14+at+23.58.13.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 4. Building the 6,11,6-Fused Tricycle https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0e663afd-c5d3-4590-a1dc-82f25b5b4567/Screenshot+2025-10-15+at+00.00.49.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 5. Assembly of the Tetrahydropyran Fragment https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4f183220-e9d0-40a8-ba36-4a896227305b/Screenshot+2025-10-15+at+00.03.33.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 6. Constructing the 5,6,7-Fused Heteroaromatic System and Final Coupling https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f8070952-10ce-4134-b461-d2eecd0c2840/Screenshot+2025-10-15+at+00.07.21.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 7. Human-directed synthesis of ABBV-453 in ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a1a12152-f90c-418e-bbca-9d35c03beb4c/Screenshot+2025-10-15+at+00.09.59.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 8. Fragment 25a – The Core Tricycle https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e471c6ee-5487-4e8b-89dd-08daccb1e40a/Screenshot+2025-10-15+at+00.13.01.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 9. Fragment 12a – The THP Motif https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8ec14627-14ee-4469-a56d-0648e54c44dc/Screenshot+2025-10-15+at+00.15.17.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 10. Fragment 12b – The Azaindole-Oxazepane Tricycle https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f8b9d8c8-969d-4777-9d5a-3757d64f6e4f/Screenshot+2025-10-15+at+00.17.07.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 11. Final Assembly https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5a76c361-010b-4fc5-8b19-692a1e122809/Screenshot+2025-10-15+at+00.19.35.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/advantages-and-challenges-of-cross-coupling-reactions-and-recent-progress-in-suzukimiyaura-reactions monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9706cbe4-cd01-4e6f-86be-cd255ccacd5c/Screenshot+2025-09-22+at+14.40.49.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6e687809-990e-4e74-aa0e-a1ea3df2af13/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+%281%29.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bfb4a6c3-c50c-4a13-8cb3-dc6f98488aea/Screenshot+2025-09-22+at+14.45.22.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 1. Recent Mechanistic Insights into Suzuki–Miyaura Cross-Coupling (2024–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1c12378e-1cbd-4da0-aeee-7f2ad44e7cef/Screenshot+2025-09-22+at+14.47.30.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 2. Recent Advances in Ligand Design and Selection for Suzuki–Miyaura Cross-Coupling (2024–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f4fb336a-4c41-4b4d-9d17-824370d92725/Screenshot+2025-09-22+at+11.13.44.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 3. Recent Advances in Boron Reagent Development for Suzuki–Miyaura Couplings (2023–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/763d04e9-803d-4e5f-8528-fbb9189bb117/Screenshot+2025-09-22+at+15.45.44.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 3. Recent Advances in Boron Reagent Development for Suzuki–Miyaura Couplings (2023–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ff59c438-f773-4849-8b5c-1d7f931d6085/Screenshot+2025-09-22+at+15.49.46.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 4. Advances in Reaction Media, Catalysis, and Scale-Up for Suzuki–Miyaura Couplings (2024–2025) https://www.chemical.ai/blog/humanai-synergy-in-retrosynthetic-analysis-and-route-optimization-of-balinatunfib monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/840536db-fcd5-44ec-af5a-714c37c9bdc1/Screenshot+2025-09-11+at+14.40.28.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 1. Crystal structure of the HUMAN TNF-ALPHA IN COMPLEX WITH CMPD 4 (PDB: 7JRA). Balinatunfib structure. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fef4bc03-5cb2-4443-9a8e-418f775984b4/Screenshot+2025-09-11+at+14.43.40.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 2. Representative Chemical Structures of TNF-α small-molecule inhibitors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/43da00c2-ed99-483c-85b6-8924cc48d4ec/Screenshot+2025-09-11+at+14.51.24.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 3. Synthetic Sequence for Fragment 1 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f2695c62-0346-4fe6-9a41-50f1cd7e1da4/Screenshot+2025-09-11+at+14.53.34.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 4. Synthetic Sequence for Fragment 1 (continued) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/07e6c36c-43cf-42d7-8306-edfbdca1e286/Screenshot+2025-09-11+at+14.55.56.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 5. Synthetic Sequence for Fragment 1 and final cross-coupling/deprotection sequence that led to balinatunfib https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f60b732c-6b67-45fa-bf1d-58f37b87c6b4/Screenshot+2025-09-11+at+15.04.59.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 6. ChemAIRS-Driven Synthesis of Balinatunfib. Route 001 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2f01c043-d454-4b79-9aed-af243c405a1f/Screenshot+2025-09-11+at+15.07.07.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 7. ChemAIRS-Driven Synthesis of Balinatunfib. Hybrid route combining R002 and R006 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d2a2a2b4-70ca-4d33-9911-4e3bcdffd2d6/Screenshot+2025-09-11+at+15.09.18.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 8. Two-Step Synthesis of Mesylate 3a from Cyclobutanone 1b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/469428e8-8376-4466-a919-a26254396eca/Screenshot+2025-09-11+at+15.11.21.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 9. Synthesis of 5a via Flow-Based Azidation/Reduction and Subsequent Two-Step Elaboration to 10b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ddb805c5-0d21-4159-a9c9-2c95eecd4de4/Screenshot+2025-09-11+at+15.12.39.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 10: Final Steps in the Synthesis of Balinatunfib https://www.chemical.ai/blog/bridging-biology-and-chemistry-bcl6-bms-986458-and-ai-predicted-routes-to-scalable-degraders monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a7767ec8-bbd8-4dcc-9fbf-30d0813532b2/Screenshot+2025-08-26+at+12.22.40%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 1. Crystal structure of the BCL6 BTB domain dimer (PDB: 1R28). Ribbon diagram representation. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7a08d077-9c34-4d60-a0d3-51ee0c4bc908/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29.jpg Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 2. Representative Chemical Structures of BCL6 Inhibitors and Degraders https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/81b0da10-6b6a-4ca1-b427-2c44cc8b5333/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 3. BMS-986458: oral cereblon-recruiting, ligand-directed BCL6 degrader https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9a698f09-5509-4dc1-90f1-4bfb6994ebc4/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+2.44.30%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 4. Construction of the indazole–piperidine-2,6-dione motif (as described in WO 2023212147A1) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/dad6a0c8-943c-4cfb-b90b-6645c839fa34/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Fig. 5: Exemplary ChemAIRS-predicted synthetic route to BMS-986458 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/18ef1e14-81ec-409f-b898-c7ba0dbdb0c3/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+3.07.05%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Fig. 6: Regioselective zincation of indazole precursors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4329e5f7-e043-41a4-9384-e382b79478dc/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+4.31.55%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Fig. 7: Nickel-catalyzed photoredox coupling https://www.chemical.ai/blog/expanding-the-therapeutic-toolbox-new-modalities-for-modern-drug-hunters monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cb44c7c5-950c-4b44-9429-57497ffdef0a/Screenshot+2025-08-15+at+09.10.13.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ffa96df2-b1b4-4c4b-b2d2-e87e04e76a7c/Screenshot+2025-08-15+at+09.12.20.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c0a93b10-916c-4b98-8270-9e4e8894c3cc/Screenshot+2025-08-15+at+09.15.07.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a23ccf37-6f66-4306-9187-adeaac5370d0/Screenshot+2025-08-15+at+09.19.31.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8c6f7d1-c27f-42bd-ae09-f1996b4c1dfd/Screenshot+2025-08-15+at+09.21.39.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/04100ff7-8f0a-41b3-a4aa-a4f2082e8f4d/Screenshot+2025-08-15+at+09.23.28.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bdf208c5-374d-4e5e-ba52-1f28489cafc8/Screenshot+2025-08-15+at+09.24.59.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/09b5dcbd-519d-4edf-be86-f6492b19daeb/Screenshot+2025-08-15+at+09.26.30.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/enabling-retrosynthetic-planning-for-radiotheranostics-chemairs-driven-synthesis-of-psma-and-ntsr1-ligands monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e838fc8a-7259-4e9a-bc44-5cd65c830e5a/chemical-structure-of-%5B177lu%5Dlu-psma-617-pluvicto Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - Chemical structure of [177Lu]Lu-PSMA-617 (Pluvicto™) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/df94fbd5-76d3-4fe0-a9f2-670aefb875da/chemairs-enabled-synthesis-of-psma-617 Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - ChemAIRS-Enabled Synthesis of PSMA-617 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2df5f02d-ee75-4dd2-9100-e2cb485fc576/chemairs-provided-a-synthetic-pathway-for-accessing-commercial-adc-linker Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - ChemAIRS provided a synthetic pathway for accessing commercial ADC linker https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fd770109-7fdc-4f43-93d5-11292988b646/chemical-structure-of-%5B225ac%5D-fpi-2059 Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - Chemical structure of [225Ac]-FPI-2059 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e97f7f1c-4979-4a00-af87-92c20f07afc7/chemairs-enabled-synthesis-of-ntsr-1%E2%80%93targeting-ligand Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - ChemAIRS-Enabled Synthesis of NTSR-1–targeting ligand https://www.chemical.ai/blog/chemairs-driven-route-design-for-macrocyclic-3clpro-inhibitors-streamlining-access-to-promising-anti-coronavirus-therapeuticsep22 monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cecb1ec5-0ff9-40fa-914d-912faff6c87a/modulators-of-coronavirus-3c-like-protease Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - Modulators of Coronavirus 3C-like Protease https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f5016016-4b7d-4308-9256-7d7a8af0a683/chemairs-enabled-scalable-synthesis-of-macrocyclic-compound-44-in-wo2025058977 Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Scalable Synthesis of Macrocyclic Compound 44 in WO2025058977 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a5ef9220-875e-4d15-8b20-6a30df85b7ff/chemairs-enabled-scalable-synthesis-of-intermediate-16a-using-reductive-cyclization-strategy Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Scalable Synthesis of Intermediate 16a using Reductive Cyclization strategy https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a4dd38ac-77bf-4071-8529-653ff364e02e/chemairs-enabled-scalable-synthesis-of-intermediate-16b-via-base-promoted-arylation Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Scalable Synthesis of Intermediate 16b via based-promoted arylation https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/87ff2ed4-6509-474d-a5a0-da67f02f145d/chemairs-enabled-streamlined-synthesis-of-macrocyclic-compound-17-in-wo2025058977 Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Streamlined Synthesis of Macrocyclic Compound 17 in WO2025058977 https://www.chemical.ai/blog/chemairs-in-action-accelerating-the-discovery-and-optimization-of-synthetic-routes-for-alks-2680-a-selective-orexin-2-receptor-agonist-developed-by-alkermesep21 monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/733fc239-fece-45ff-a7f4-bd6ee00fb51c/ALKS+2680+%28alixorexton%29 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ALKS 2680 (alixorexton) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7bf2a603-4f67-47c6-89ed-d6b798af699a/alkermes%27s-published-synthetic-route-to-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - Alkermes's published synthetic route to ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ef0c2e63-507c-4819-963b-511b3af4bfb6/chemairs-suggested-retrosynthesis-analysis-of-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS suggested Retrosynthesis Analysis of ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c89d0c9c-d7c5-48d6-b96b-f90b068d2018/%22chemairs-generated-alternative-discovery-route-to-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS generated alternative Discovery Route to ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a347acc1-1178-4476-a755-38c9b805a664/chemairs-suggested-scalable-synthetic-route-to-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS suggested Scalable Synthetic Route to ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/34e5a168-2160-41bb-bdfb-82874d9cce14/chemairs-selected-commercially-available-bulk-starting-materials-for-alks-2680-production Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS Selected Commercially Available Bulk Starting Materials for ALKS 2680 Production https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a793571a-b30e-4903-b152-d2f621f6e5aa/chemairs-suggested-scale-up-reaction-condition-for-the-cyclization-step Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS suggested scale-up reaction condition for the cyclization step https://www.chemical.ai/blog/chemairs-driven-retrosynthesis-of-elironrasib-rmc-6291-a-next-gen-kras-g12con-inhibitorep19nbsp monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/280a1040-2a9f-40e1-973c-4620769592bb/rmc-6291-a-next-gen-kras-g12c-on-inhibitor-from-revolution-medicines Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - RMC-6291: A Next-Gen KRAS-G12C(ON) Inhibitor from Revolution Medicines https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7c725190-fae8-4362-a7cf-6ca5e94958bc/chemairs-retrosynthetic-strategy-toward-elironrasib-rmc-6291 Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS Retrosynthetic Strategy Toward Elironrasib (RMC-6291) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c1f5a1ee-21a2-45ea-b32e-487b19b4ce68/key-fragmentation-intermediates-for-elironrasib-retrosynthesis Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - Key fragmentation intermediates for Elironrasib retrosynthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3904d6a4-f46e-4632-96e2-d45f08ac066b/chemairs-generated-synthetic-pathway-for-fluoropiperidine-intermediate Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS-Generated Synthetic Pathway for fluoropiperidine Intermediate https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/74164d39-f032-4fb1-a824-3bfae274b9a6/retrosynthetic-fragmentation-of-intermediate-25b-into-building-blocks-12a-12b-and-14b Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - Retrosynthetic fragmentation of intermediate 25b into building blocks 12a, 12b, and 14b. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9356d2e6-e296-41a6-a96d-0ed6be3da1ed/chemairs-generated-synthetic-pathway-for-macrocyclic-intermediate-25b Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS-Generated Synthetic Pathway for Macrocyclic Intermediate 25b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/18401721-442c-4f70-903d-fcd2ee7cf3b0/cost-effective-route-to-s-methyl-hexahydropyridazine-3-carboxylate-chemairs-enabled-3-step-synthesis-avoids-procurement-challenges Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - Cost-effective route to (S)-Methyl hexahydropyridazine-3-carboxylate: ChemAIRS-enabled 3-step synthesis avoids procurement challenges https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cca09c25-6006-4c90-8868-22322c68f9d0/chemairs-identified-potential-competing-side-reactions Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS identified potential competing side reactions https://www.chemical.ai/blog/chemairs-optimizes-the-synthesis-of-novo-nordisks-glucose-sensitive-derivativesep19 monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0f3b1599-30f3-4b0f-ad4d-54821cc7828a/novo-nordisk%E2%80%99s-diboron-based-glucose-sensitive-insulins.png Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - Novo Nordisk’s Diboron-Based Glucose-Sensitive Insulins https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1ac5590a-490e-40d9-8a45-a52873b0ab7d/chemairs-outlines-synthesis-strategies-for-diboron-based-glucose-sensitive-insulins.png Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS Outlines Synthesis Strategies for Diboron-Based Glucose-Sensitive Insulins https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/98f046f5-1e43-490d-a588-38075b579f03/chemairs-identified-a-potential-competing-side-reaction Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS identified a potential competing side reaction https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ee0921f3-3f5c-4003-a79f-32372b84d6c2/chemairs-optimized-synthesis-diboron-glucose-sensitive-derivatives Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS reveals optimized strategies for enhanced synthesis of Diboron-Based Glucose-Sensitive Derivatives https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9335f713-0553-46ca-92a0-9b5ccc4fd7c1/chemairs-identified-alternative-borylation-conditions-to-enhance-reaction-performance Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS identified alternative borylation conditions to enhance reaction performance https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/53957ba1-c547-4dec-b02b-e1a746e770b6/chemairs-miyaura-borylation-optimization-b%E2%82%82neop%E2%82%82-ultra-low-pd Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS optimizes Miyaura borylation: B₂(neop)₂ replaces B₂Pin₂, enabling ultra-low Pd with Pd(PCy₃)₂Cl₂/base https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d74c18c5-4a92-4a9c-aebc-243512275416/chemairs-optimized-parameters-scalable-synthesis Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS delivers optimized reaction parameters for robust and scalable synthesis https://www.chemical.ai/blog/lchemairs-to-investigate-synthetic-strategies-for-sgr-1505-a-malt1-inhibitor-from-schrodinger monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c3e7db3c-e854-421d-8fc7-ae5639f6cefb/sgr-1505-as-a-novel-therapeutic-approach-for-cancer-treatment Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - SGR-1505 as a Novel Therapeutic Approach for Cancer Treatment https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e68fcb07-83d8-4a27-a8ae-b15ec8858808/chemairs-predicted-a-synthetic-pathway-for-an-sgr-1505 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS predicted a synthetic pathway for an SGR-1505 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0a679f8a-45b2-47ab-ae09-814c5b447431/chemairs-suggested-two-reaction-conditions-for-intramolecular-cyclization Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS suggested two reaction conditions for intramolecular cyclization https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f2b37377-f4d7-4742-91b1-075711fa21f1/chemairs-proposed-an-alternative-synthetic-strategy-to-obtain-sgr-1505 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS Proposed An alternative synthetic strategy to obtain SGR-1505 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fc166565-18b0-4311-a376-38d863069f50/chemairs-suggested-reaction-conditions-for-asymmetric-methylation Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS Suggested reaction conditions for asymmetric methylation https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ac1e5b37-ca89-452f-8793-1c2ba938fd8e/alternative-substrates-involved-a-palladium-catalyzed-amination-and-a-transamidation Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - Alternative substrates involved a palladium-catalyzed amination and a transamidation https://www.chemical.ai/blog/chemairs-to-explore-synthetic-strategies-of-ab521-an-hif-2-inhibitor-from-arcus-bioscience monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f18fc149-6f67-4918-9b25-ae5653f73870/targeting-hif-2%CE%B1-ab521-%28casdatifan%29-as-a-promising-antitumor-agent-in-cancer-therapy Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - Targeting HIF-2α: AB521 (Casdatifan) as a Promising Antitumor Agent in Cancer Therapy https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/834e4b5f-d08a-459b-bdc6-b04ba35110e3/chemairs-predicted-a-synthetic-pathway-for-ab521 Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - ChemAIRS predicted a synthetic pathway for AB521 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7bc490e7-e56e-4328-99f9-40a24c353b27/chemairs-proposed-an-alternative-way-to-synthesize-intermediate-7a-due-to-the-aldehyde-functionality Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - ChemAIRS proposed An alternative way to synthesize intermediate 7a due to the aldehyde functionality https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/16616878-343c-4828-a0ca-440137a13bb7/potential-side-reactions-for-the-synthesis-of-intermediate-10b-in-ab521-synthesis Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - Potential side reactions for the synthesis of intermediate 10b in AB521 synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/18b9cd49-c894-48db-ac4d-6ac69f8bb113/chemairs-proposed-alternative-synthetic-route-for-ab521 Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - ChemAIRS proposed Alternative synthetic route for AB521 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/eafc748a-9c6f-492a-a297-02ad18e1567e/reference-reactions-for-the-enantioselective-mono-fluorination-to-intermediate-3a Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - Reference reactions for the enantioselective mono-fluorination to intermediate 3a https://www.chemical.ai/blog/streamlining-the-synthesis-of-novartis-wrn-inhibitor-hro761-with-chemairs-a-promising-therapeutic-for-msi-cancers monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/458c7660-1701-4bb3-892c-74179bd6d835/novartis%E2%80%99-wrn-inhibitor-hro761-a-promising-therapeutic-for-msi-cancers Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - Novartis’ WRN Inhibitor HRO761, A Promising Therapeutic for MSI Cancers https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c4709c0b-492c-4fef-a594-3ad54424ea0c/chemairs-predicted-a-synthetic-pathway-for-novartis%27s-wrn-inhibitor-hro761-closely-aligned-with-the-published-route Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - ChemAIRS predicted a synthetic pathway for Novartis's WRN inhibitor HRO761, closely aligned with the published route https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fb580df3-5f78-4c06-ab19-94c899f1ff4c/chemairs-identified-side-reaction-risk-for-the-last-step-synthesis-of-hro761 Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - ChemAIRS identified side reaction risk for the last-step synthesis of HRO761 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d0b80828-ede1-42f1-bb56-582b2140b87f/chemairs-suggested-an-alternative-synthetic-pathway-for-wrn-inhibitor-hro761-to-mitigate-final-step-risks Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - ChemAIRS suggested an alternative synthetic pathway for WRN inhibitor HRO761 to mitigate final step risks https://www.chemical.ai/blog/chemairs-to-unveil-synthetic-strategies-for-selective-cannabinoid-receptor-2-inverse-agonists monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/64586fe9-ab6c-4af4-81d7-d677d9c13a62/advances-in-cb2-inverse-agonists-exploring-therapeutic-potential-and-selectivity Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - Advances in CB2 Inverse Agonists: Exploring Therapeutic Potential and Selectivity https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a75de9e5-cafb-4fc5-a669-228670fc143c/chemairs-predicted-a-synthetic-pathway-for-cb2r-inverse-agonists Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS predicted a synthetic pathway for CB2R inverse agonists https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ce44a5a9-2772-40ce-95b1-7747fb6149bd/chemairs-identified-potential-side-reaction-for-the-synthesis-of-intermediate-9a Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS identified Potential side reaction for the synthesis of intermediate 9a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e68185f7-4b49-4688-9fdb-d9b155a48e65/chemairs-proposed-alternative-synthetic-route-for-cb2r-inverse-agonists Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS Proposed Alternative synthetic route for CB2R inverse agonists https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/51aa2fe0-0928-4686-8789-122ce956174a/chemairs-identified-potential-side-reaction-for-the-synthesis-of-intermediate-4a Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS identified Potential side reaction for the synthesis of intermediate 4a https://www.chemical.ai/blog/chemairs-to-investigate-synthetic-strategies-for-chiral-spirocyclic-isoxazolone-a-vital-building-block-in-a-boehringer-ingelheim-drug-development-program monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/51534280-5856-439c-8764-232b592bbb6a/chiral-spirocyclic-isoxazolone-a-vital-building-block-in-a-boehringer-ingelheim-drug-development-program Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/79b68c9e-05dc-4ed4-a651-ba3d733d4026/chemairs-predicted-a-synthetic-pathway-for-spirocyclic-isoxazolone-starting-from-a-commercially-available-starting-material-1b Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS predicted a synthetic pathway for spirocyclic isoxazolone, starting from a commercially available starting material 1b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/208ee12b-7353-4c39-85f0-176f6acabb01/suggested-reaction-conditions-for-scaling-up-intermediate-3a Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS Suggested reaction conditions for scaling up intermediate 3a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bbd06cb9-b4cd-4508-90d4-307a0a7f3ecb/potential-side-reaction-for-the-synthesis-of-3a Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - Potential side reaction for the synthesis of 3a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/62e73991-27c9-479f-a3a0-5a0f9375e54d/chemairs-proposed-alternative-synthetic-route-for-spirocyclic-isoxazolone Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS proposed Alternative synthetic route for spirocyclic isoxazolone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/df899b74-7d88-4413-af89-54ad50af51f1/chemairs-identified-potential-side-reaction-for-the-synthesis-of-4a Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS identified Potential side reaction for the synthesis of 4a https://www.chemical.ai/blog/chemairs-to-explore-synthetic-strategies-of-azabenzimidazolone-a-potent-v1-integrin-antifibrotic-by-takeda monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/34409b21-963a-4083-b724-b3db7e4dbcb9/azabenzimidazolone-as-a-potent-antifibrotic-agent-targeting-%CE%B1v%CE%B21-integrin Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - Azabenzimidazolone as a Potent Antifibrotic Agent Targeting αvβ1 Integrin https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/38a63b68-7812-4af0-abb1-9da8ad9f3fc0/chemairs-proposed-a-synthetic-pathway-for-azabenzimidazolone-recommending-the-ring-closing-reaction-as-the-final-step Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - ChemAIRS proposed a synthetic pathway for Azabenzimidazolone, recommending the ring-closing reaction as the final step https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ddda03e1-a25c-43b9-9fdc-1350ab2bb514/chemairs-detected-potential-side-reactions-during-the-synthesis-of-intermediate-7a-in-azabenzimidazolone-synthesis Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - ChemAIRS detected potential side reactions during the synthesis of intermediate 7a in Azabenzimidazolone synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6fe1d497-858a-4738-9d8d-a8447a27749f/alternative-synthetic-route-for-azabenzimidazolone-suggested-by-chemairs Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - Alternative Synthetic Route for Azabenzimidazolone suggested by ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5094da62-bdb2-4fdf-8b1d-d4d0be3b9a61/chemairs-reaction-site-analysis-for-the-synthesis-of-intermediate-7a Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - ChemAIRS reaction site analysis for the synthesis of intermediate 7a https://www.chemical.ai/blog/chemairs-to-investigate-synthesis-strategies-of-ox2r-modulator-a-vertex-pharmaceuticals-approach-to-narcolepsy-treatment monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2e9ea6c3-a957-419c-91f1-ef1291ef5c18/macrocyclic-amine-modulators-targeting-ox2r-a-promising-narcolepsy-treatment Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Macrocyclic Amine Modulators Targeting OX2R: A Promising Narcolepsy Treatment https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e0b1c026-a14b-4e62-8c26-6b9f45d7f15b/chemairs-predicted-a-synthetic-pathway-for-an-ox2r-modulator-which-closely-aligns-with-vertex%27s-patented-report Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - ChemAIRS predicted a synthetic pathway for an OX2R modulator, which closely aligns with Vertex's patented report https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a0ed507c-195a-464d-929f-8b9025a1d6e5/proposed-cost-effective-synthetic-strategy-for-13a-from-chemairs Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Proposed cost-effective synthetic strategy for 13a from ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3572c7d5-1840-4718-81c7-050d48d941c5/alternative-synthetic-routes-for-the-ox2r-modulator-initiated-with-the-preparation-of-two-chiral-intermediates Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Alternative Synthetic Routes for the OX2R Modulator, initiated with the preparation of two chiral intermediates https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/302ac56f-bbeb-4798-962f-572fd17c7987/alternative-synthetic-routes-for-ox2r-modulator-featuring-the-formation-of-the-macrocyclic-molecule-through-intramolecular-etherification Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Alternative Synthetic Routes for OX2R Modulator, featuring the formation of the macrocyclic molecule through intramolecular etherification https://www.chemical.ai/blog/rapidly-identifying-alternative-synthetic-routes-for-mercks-kras-g12c-inhibitor monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1833ab4c-3bc5-49d4-b07e-43abac4afd49/merck%27s-discovery-of-selective-g12c-inhibitors-for-kras-mutant-cancers Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - Merck's Discovery of Selective G12C Inhibitors for KRAS-Mutant Cancers https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/aa3cacc4-6064-4ab7-bf18-95f03c28fe37/chemairs-predicted-a-synthetic-pathway-for-merck%27s-kras-inhibitor-closely-aligned-with-the-published-route Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS predicted a synthetic pathway for Merck's KRAS inhibitor, closely aligned with the published route https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/97955692-f4b4-4d42-a170-94737ddf24ab/chemairs-suggested-an-alternative-synthetic-route-for-6b-a-key-intermediate-for-route-optimization-of-kras-inhibitor Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS suggested an alternative synthetic route for 6b, a key intermediate for route optimization of KRAS inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/60df85f1-15c8-4774-9b33-1ddb61bb668a/chemairs-identified-functional-group-compatibility-risk-for-compound-3a-and-suggested-alternative-reaction-conditions Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS identified functional group compatibility risk for compound 3a and suggested alternative reaction conditions https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/046498d5-60a0-4b60-949f-7ab8899536e9/chemairs-analyzed-the-reaction-site-for-compound-3a-to-advise-users-on-potential-side-reactions Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS analyzed the reaction site for compound 3a to advise users on potential side reactions https://www.chemical.ai/blog/exploring-the-synthesis-of-janssens-rsv-f-inhibitor-usingchemairs monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/08d85f86-c3b3-41be-bc21-6e02af6a2687/spiro-azetidine-oxindole-sulfonamide-derivative-exhibiting-potent-inhibition-of-the-rsv-fusion-protein Blog - Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03 - Spiro-azetidine oxindole sulfonamide derivative, exhibiting potent inhibition of the RSV fusion protein https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8cfb86a-1f55-491e-b18f-cec4ce1b042c/chemairs-proposed-retrosynthetic-strategy-for-spiro-azetidine-oxindole-sulfonamide-a-potent-rsv-fusion-inhibitor Blog - Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03 - ChemAIRS Proposed Retrosynthetic Strategy for Spiro-Azetidine Oxindole Sulfonamide, a Potent RSV Fusion Inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abaad3ff-d43f-451c-bc77-3fb94b5a0572/chemairs-identified-cost-efficient-synthetic-route-to-spiro-azetidine-oxindole-sulfonamide Blog - Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03 - ChemAIRS-Identified Cost-Efficient Synthetic Route to Spiro-Azetidine Oxindole Sulfonamide https://www.chemical.ai/blog/chemairs-to-investigate-synthesis-strategy-of-prmt5-inhibitor-from-gilead-sciences monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c3531d53-7a87-4291-a9c5-d840891002ac/prmt5-has-emerged-as-a-promising-and-valuable-target-for-cancer-epigenetic-therapy Blog - Utilizing ChemAIRS to investigate synthesis strategy of PRMT5 inhibitor from Gilead Sciences_EP01 - PRMT5 has emerged as a promising and valuable target for cancer epigenetic therapy https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1ba1879f-ac6b-4a94-bcae-ba7868f26510/chemairs%27-proposed-synthetic-pathway-for-prmt5-inhibitor Blog - Utilizing ChemAIRS to investigate synthesis strategy of PRMT5 inhibitor from Gilead Sciences_EP01 - ChemAIRS' Proposed synthetic Pathway for PRMT5 inhibitor https://www.chemical.ai/blog/optimizing-synthetic-strategies-of-genentechs-epb-inhibitor-with-chemairs monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3d9e572b-aab7-4035-8685-101ba9af5670/emopamil-binding-protein-%28ebp%29-as-a-promising-in-vivo-tool-molecule-for-further-assessment-of-potential-remyelination-therapies Blog - Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02 - emopamil binding protein (EBP) as a promising in vivo tool molecule for further assessment of potential remyelination therapies https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/40808ea4-ec0b-4436-b219-497792f80f19/Scheme+1.PNGchemairs-proposed-synthetic-pathway-to-an-ebp-inhibitor Blog - Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02 - ChemAIRS' Proposed Synthetic Pathway to an EBP inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e4ed0580-9b09-4401-9b65-e36938699684/chemairs-proposed-alternative-synthetic-pathway-to-an-ebp-inhibitor-with-a-different-set-of-starting-materials Blog - Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02 - ChemAIRS’ Proposed Alternative Synthetic Pathway to an EBP inhibitor, With a different set of starting materials https://www.chemical.ai/blog/chemairs-to-accelerate-discovery-of-synthetic-strategies-for-kt474-a-selective-orally-bioavailable-heterobifunctional-irak4-degrader-from-kymera-therapeutics monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3c18abce-2142-4ed4-b691-13417b7c2437/KT-474-a+first-in-class-selective-and-orally-bioavailable-heterobifunctional-IRAK4-degrader.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - KT-474: A First-in-Class IRAK4 Degrader Advancing Autoimmune and Inflammatory Disease Therapies https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abfd6b86-e213-4bf8-aced-7304048c62eb/chemAIRS-predicted-a-synthetic-pathway-for-KT-474.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - ChemAIRS predicted a synthetic pathway for KT-474, which closely parallels the synthetic pathway previously reported by Kymera Therapeutics https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/08ed3cc2-3dd2-449a-9360-0487acd474c7/chemairs-proposed-alternative-reaction-conditions-to-kt-474.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e4dcb0a2-2754-4fae-b877-44428c9f05da/chemairs-proposed-alternative-synthetic-pathway-to-kt-474.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - ChemARIS Proposed Alternative synthetic pathway to KT-474 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ba0dfe93-745b-4b3f-b975-d61fd32946fe/chemairs-identified-a-potential-side-reaction-in-the-coupling-step-of-KT-474-and-proposed-optimireaction-conditions-to-minimize-its-occurrence.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - ChemAIRS identified a potential side reaction in the final coupling step to KT-474 and proposed optimized reaction conditions to minimize its occurrence. https://www.chemical.ai/blog/enhancing-synthetic-pathways-and-tackling-impurities-how-chemairs-supports-the-synthesis-of-4-chloro-123-triazole-for-milvexian monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0e79fb6b-fb1c-46bd-bf8d-c4b56e962a1b/4-chloro-1%2C2%2C3-triazole-a-critical-intermediate-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - 4-chloro-1,2,3-triazole, a critical intermediate in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1cdb5322-9cad-4f80-bb59-4c532d441c74/chemairs-predicts-a-synthetic-pathway-for-4-chloro-1%2C2%2C3-triazole-in-milvexian-synthesis-aligned-with-bristol-myers-squibb%27s-approach Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS Predicts a Synthetic Pathway for 4-Chloro-1,2,3-Triazole in Milvexian synthesis which is Aligned with Bristol Myers Squibb's Approach https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3c4259ee-b55f-4c3e-979e-4b524380db14/discover-chemairs%27-proposed-synthetic-route-for-4-chloro-1%2C2%2C3-triazole-in-milvexian-synthesis-highlighting-triazole-enabled-ruthenium-catalyzed-c-h-arylations.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - Discover ChemAIRS' proposed synthetic route for 4-Chloro-1,2,3-Triazole in Milvexian synthesis, highlighting triazole-enabled ruthenium-catalyzed C–H arylations https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4a8e8778-3255-41fe-bd44-42836821f8e8/chemairs-identifies-potential-side-reactions-as-risk-items-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS identifies potential side reactions as risk items in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/922512e0-d2ad-434a-8556-f4dd0cf839d0/impurity-identified-in-the-suzuki-miyaura-coupling-step-as-reported-by-bristol-myers-squibb-in-milvexian-synthesis.jpg Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - Impurity identified in the Suzuki-Miyaura coupling step, as reported by Bristol Myers Squibb in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/42ee762f-cefe-45a4-a03f-d9f18774c0e8/chemairs-predicts-impurity-structures-for-the-suzuki-miyaura-coupling-step-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS predicts impurity structures for the Suzuki-Miyaura coupling step in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2eae142e-0ae2-4bd9-a043-c60c47867cc9/impurity-identified-in-the-chlorination-step-as-reported-by-bristol-myers-squibb-in-milvexian-synthesis.jpg Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - Impurity identified in the chlorination step, as reported by Bristol Myers Squibb in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/94ea4113-a69a-4abd-8601-14dbd69b3ddb/chemairs-predicts-impurity-structures-for-the-chlorination-step-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS predicts impurity structures for the chlorination step in Milvexian synthesis https://www.chemical.ai/blog/chemairs-to-explore-synthetic-strategies-for-bay-2413555-a-bayer-therapeutic-candidate-targeting-heart-failure monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b5e8158b-c27a-4915-88e0-a966efeced7f/bay-2413555-a-selective-and-reversible-m%E2%82%82-receptor-m2r-positive-allosteric-modulator-pam.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - BAY 2413555, a selective and reversible M₂ receptor (M2R) positive allosteric modulator (PAM), was developed to enhance parasympathetic signaling and restore cardiac autonomic balance https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/96cb34f5-3a39-420a-936a-580a71793978/chemairs-proposed-retrosynthetic-strategy-for-bay-2413555.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS-Proposed Retrosynthetic Strategy for BAY 2413555 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8dada00-32a8-4142-b170-872eaf78436a/chemairs-proposed-additional-strategies-for-the-pentafluoroalkyl-amine-an-intermediate-in-synthesis-of-bay-2413555.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS-Proposed Additional Atrategies for the Pentafluoroalkyl Amine, an intermediate in synthesis of BAY 2413555 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3988e79c-27ba-4722-b9b0-5e6dfdd509e2/chemairs-suggested-alternative-pathway-to-bay-2413555-where-amide-formation-was-strategically-shifted-earlier-in-the-sequence.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS-Suggested Alternative Pathway to BAY 2413555, where amide formation was strategically shifted earlier in the sequence https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0b1098ae-f6a0-4928-8995-178f8f0d8ea5/chemairs-proposed-optimized-scale-up-conditions-for-the-amidation-step.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS Proposed Optimized Scale-Up Conditions for the amidation step in synthesis of BAY 2413555 https://www.chemical.ai/blog/chemairs-to-investigate-synthetic-approaches-for-azetidine-based-v6-integrin-inhibitors-core-modifications-of-gsk3335103 monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e9a3f3bf-f498-458b-9e08-759ce5203b65/%CE%B1v%CE%B26-inhibitors-from-gsk-building-on-their-earlier-compounds-gsk3008348-and-gsk3335103.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - αvβ6 inhibitors from GSK, building on their earlier compounds GSK3008348 and GSK3335103 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0e849249-b021-457c-81f6-76aed2f79654/chemairs-proposed-synthetic-strategy-for-gsk%27s-azetidine-based-%CE%B1v%CE%B26-integrin-inhibitors.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS-Proposed Synthetic Strategy for GSK's Azetidine-Based αvβ6 Integrin Inhibitors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ac455852-b557-40a8-ade9-cc1c3e74e13a/wittig-reaction-driven-synthesis-of-a-difluoroazetidine-intermediate.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - Wittig Reaction-Driven Synthesis of a Difluoroazetidine Intermediate https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1a118452-552a-4690-96b3-6aa2923638f6/horner%E2%80%93wadsworth%E2%80%93emmons-reaction-for-the-synthesis-of-a-fluoroazetidine-intermediate.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - Horner–Wadsworth–Emmons Reaction for the Synthesis of a Fluoroazetidine Intermediate https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/90459af2-a827-4927-82c1-7b4b1864131e/chemairs-identified-a-potential-side-reaction-in-the-conjugate-addition-of-arylboronic-acid-to-4-oxoisocrotonic-acid.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS Identified a Potential Side Reaction in the conjugate addition of arylboronic acid to 4-oxoisocrotonic acid https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/decc4beb-9833-4b64-9cd9-9fc973e79785/chemairs%27-proposed-alternative-pathway-to-synthesize-diphosphorylated-intermediate-considering-safety-issue-of-starting-materials.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS' proposed Alternative pathway to synthesize diphosphorylated intermediate, considering safety issue of starting materials https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fa68108b-a106-430c-8159-16866d7faba4/chemairs-proposed-synthetic-strategy-for-gsk%27s-azetidine-based-%CE%B1v%CE%B26-integrin-inhibitors.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS-Proposed Synthetic Strategy for GSK's Azetidine-Based αvβ6 Integrin Inhibitors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e334bb06-bea5-46ee-be1a-4b32ffb9574b/chemairs-proposed-optimized-scale-up-conditions-for-a-reductive-amination.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS Proposed Optimized Scale-Up Conditions for a reductive amination https://www.chemical.ai/blog/chemairs-to-investigate-synthesis-strategies-for-azd5462-a-promising-rxfp1-agonist-for-heart-failure-treatment monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/47a60d12-f028-478f-a6fa-0d514951a886/azd5462-a-small-molecule-mimetic-of-relaxin-h2-signaling-at-rxfp1-offering-promise-as-a-treatment-for-heart-failure.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - AZD5462, a small-molecule mimetic of relaxin H2 signaling at RXFP1, offering promise as a treatment for heart failure https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4d33ab09-a2a0-47a2-bca4-bdb61f3e2f04/chemairs-predicted-a-19-step-synthetic-pathway-for-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS predicted a 19-step synthetic pathway for AZD5462 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b9810f70-dd22-4f3d-9ed2-a9237c58eb18/chemairs-proposed-efficient-synthetic-route-for-1-methylcyclobutyl-methanamine.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS proposed efficient synthetic route for (1-methylcyclobutyl)methanamine https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/54ea9cd6-7b0f-4914-ac39-8cc25a8db749/chemairs%27-proposed-alternative-scale-up-conditions-in-coupling-reaction-for-one-intermediate-of-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS' Proposed alternative scale-up conditions in coupling reactionfor one intermediate of AZD5462 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/82ec7eea-8eb6-4348-b852-2203f3370083/chemairs-predicted-possible-side-reaction-in-the-synthesis-of-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS predicted Possible side reaction in the synthesis of AZD5462 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2a5fa18e-1e6d-45e8-88ec-b1da5bc1fc86/chemairs-proposed-alternative-synthetic-strategy-to-obtain-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS proposed alternative synthetic strategy to obtain AZD5462 https://www.chemical.ai/blog/retrosynthetic-strategy-for-orforglipron-ly3502970-using-chemairs-developing-a-more-streamlined-and-efficient-synthetic-route-suggestion monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8ebb66c2-2fa5-4918-bd97-a6b2999854d4/orforglipron-ly3502970-an-orally-bioavailable-non-peptide-glp-1ra-eliminates-the-need-for-absorption-enhancers Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - Orforglipron (LY3502970), an orally bioavailable non-peptide GLP-1RA, eliminates the need for absorption enhancers https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b9a721aa-4c4c-437f-a0fc-9e8b4aa0c87d/chemairs%27-proposed-approach-for-the-synthesis-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' proposed approach for the synthesis of Orforglipron https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ea34b7f3-aac0-42c2-aeaf-68c31561c9c5/chemairs%27-proposed-synthetic-route-for-the-imidazol-2-one-intermediate-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' proposed synthetic route for the imidazol-2-one intermediate of Orforglipron https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5f236196-5e41-478e-bfe4-cf3a69d6ce1d/chemairs%27-proposed-optimized-scale-up-conditions-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' Proposed Optimized Scale-Up Conditions of Orforglipron https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b0b5763b-4b8c-4dc4-99a1-ff06a2fc63a1/%22chemairs%27-proposed-synthetic-route-for-the-indole-2-carboxylic-acid-intermediate-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' proposed synthetic route for the indole-2-carboxylic acid intermediate of Orforglipron https://www.chemical.ai/blog/chemairs-to-investigate-synthetic-strategies-for-tetrahydrobenzoazepine-core-of-btk-inhibitor-biib091 monthly 0.5 2026-04-21 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6f337992-866e-4483-867f-3c79aa1a83cb/tetrahydrobenzoazepine-core-of-btk-inhibitor-biib091.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1f7cfbc9-4449-4760-93ee-0db36164bccb/chem-airs-proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-friedel-crafts-acylation-to-construct-the-benzazepine-core-from-an-n-boc-ketone.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - Chem AIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Friedel-Crafts acylation to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0acea6b4-0a8c-4214-9cce-2e23e1bb1d5a/chemairs-proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-friedel-crafts-acylation-to-construct-the-benzazepine-core-from-an-n-boc-ketone Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Friedel-Crafts acylation to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1240ba65-0af2-4df1-8642-9a75208f10f5/proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-intramolecular-pd-catalyzed-heck-reaction-to-construct-the-benzazepine-core-from-an-n-boc-ketone.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Intramolecular Pd-Catalyzed Heck Reaction to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d8ad4e9f-5d1c-4911-bf76-37fc2460c7f2/chemairs-proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-ester-aryl-halide-cyclization-to-construct-the-benzazepine-core-from-an-n-boc-ketone.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Ester-Aryl Halide Cyclization to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/00f8545a-727f-495d-8599-8cf36bfe03ac/alternative-reaction-condition-for-synthesizing-btk-inhibitor-biib091.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - Alternative Reaction Condition for Synthesizing BTK Inhibitor BIIB091 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ed9572c4-53e2-4a85-a0bc-0fdbfa076806/chemairs-proposed-alternative-reaction-conditions-for-friedel-crafts-acylation.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed Alternative Reaction Conditions for Friedel-Crafts Acylation https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8316ac0e-b927-4795-b901-ff48294d71da/chemairs%27-proposed-potential-side-reaction-during-friedel-crafts-acylation-in-synthesizing-btk-inhibitor-biib091 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS' proposed Potential Side Reaction During Friedel-Crafts Acylation in synthesizing BTK Inhibitor BIIB091 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/73d583d1-ab5d-45ff-be4b-3a85182639c9/chemairs%27-proposed-alternative-reaction-conditions-for-intramolecular-pd-catalyzed-heck-reaction-in-synthesizing-btk-inhibitor-biib091 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS' proposed Alternative Reaction Conditions for Intramolecular Pd-Catalyzed Heck Reaction in synthesizing BTK Inhibitor BIIB091 https://www.chemical.ai/blog/category/Synthesis+Planning monthly 0.5 https://www.chemical.ai/blog/category/Precision+%26+Targeted+Medicine monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+Methodology monthly 0.5 https://www.chemical.ai/blog/category/Metabolic+%26+Endocrine+Therapeutics monthly 0.5 https://www.chemical.ai/blog/category/Insecticides monthly 0.5 https://www.chemical.ai/blog/category/Retrosynthesis monthly 0.5 https://www.chemical.ai/blog/category/AI+in+Pharmaceuticals monthly 0.5 https://www.chemical.ai/blog/category/Computer-Aided+Synthesis+Planning+%28CASP%29 monthly 0.5 https://www.chemical.ai/blog/category/Computational+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Artificial+Intelligence+in+Pharma monthly 0.5 https://www.chemical.ai/blog/category/Oncology+Research monthly 0.5 https://www.chemical.ai/blog/category/Pharmaceutical+Innovation monthly 0.5 https://www.chemical.ai/blog/category/AI+in+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+Accessibility monthly 0.5 https://www.chemical.ai/blog/category/Crop+Protection monthly 0.5 https://www.chemical.ai/blog/category/Oncology+%26+Disease+Applications monthly 0.5 https://www.chemical.ai/blog/category/AI+in+Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/category/Clinical+Trials+%26+Therapeutics monthly 0.5 https://www.chemical.ai/blog/category/Case+Study monthly 0.5 https://www.chemical.ai/blog/category/Process+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Artificial+Intelligence+in+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Materials+Science monthly 0.5 https://www.chemical.ai/blog/category/Organic+Electronics monthly 0.5 https://www.chemical.ai/blog/category/Drug+Discovery+%26+Development monthly 0.5 https://www.chemical.ai/blog/category/Therapeutic+Modalities+%26+Mechanisms monthly 0.5 https://www.chemical.ai/blog/category/Chemical+R%26D monthly 0.5 https://www.chemical.ai/blog/category/Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/category/Molecular+Design monthly 0.5 https://www.chemical.ai/blog/category/Materials+chemistry monthly 0.5 https://www.chemical.ai/blog/category/Medicinal+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+%26+Medicinal+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Clinical+Trials+%26+Regulatory+Insights monthly 0.5 https://www.chemical.ai/blog/category/Agrochemistry monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Digital+Chemistry+Tools monthly 0.5 https://www.chemical.ai/blog/category/OLED+materials monthly 0.5 https://www.chemical.ai/blog/category/Process+Optimization monthly 0.5 https://www.chemical.ai/blog/category/Drug+Development monthly 0.5 https://www.chemical.ai/blog/category/Oncology+Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/category/Human%E2%80%93AI+Collaboration monthly 0.5 https://www.chemical.ai/blog/tag/TNF-%CE%B1+Inhibitors monthly 0.5 https://www.chemical.ai/blog/tag/Elironrasib+%28RMC-6291%29 monthly 0.5 https://www.chemical.ai/blog/tag/Retrosynthesis+prediction monthly 0.5 https://www.chemical.ai/blog/tag/Room-Temperature+Phosphorescence monthly 0.5 https://www.chemical.ai/blog/tag/TADF monthly 0.5 https://www.chemical.ai/blog/tag/Retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/Surzetoclax+synthesis monthly 0.5 https://www.chemical.ai/blog/tag/ChemAIRS+Retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/Computational+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/AI+retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/Oncology+Drug+Development monthly 0.5 https://www.chemical.ai/blog/tag/decarboxylative+cross-coupling monthly 0.5 https://www.chemical.ai/blog/tag/Pharmaceutical+Development monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+Route+Optimization monthly 0.5 https://www.chemical.ai/blog/tag/AI+in+Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/tag/Sanofi monthly 0.5 https://www.chemical.ai/blog/tag/Precision+Medicine monthly 0.5 https://www.chemical.ai/blog/tag/Chemical+AI monthly 0.5 https://www.chemical.ai/blog/tag/PROTACs monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+accessibility+score monthly 0.5 https://www.chemical.ai/blog/tag/bms-986458+synthesis monthly 0.5 https://www.chemical.ai/blog/tag/retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/Reaction+Mechanism monthly 0.5 https://www.chemical.ai/blog/tag/KRAS-G12C%28ON%29+Inhibitors monthly 0.5 https://www.chemical.ai/blog/tag/agrochemistry monthly 0.5 https://www.chemical.ai/blog/tag/Lymphoma+Therapy+Synthetic+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/RNA+Therapeutics monthly 0.5 https://www.chemical.ai/blog/tag/ChemAIRS monthly 0.5 https://www.chemical.ai/blog/tag/Impurity+Analysis monthly 0.5 https://www.chemical.ai/blog/tag/Orforglipron+%28LY3502970%29 monthly 0.5 https://www.chemical.ai/blog/tag/UCB+Pharma monthly 0.5 https://www.chemical.ai/blog/tag/ABBV-453 monthly 0.5 https://www.chemical.ai/blog/tag/Eli+Lilly monthly 0.5 https://www.chemical.ai/blog/tag/Bristol+Myers+Squibb monthly 0.5 https://www.chemical.ai/blog/tag/RTP+Materials monthly 0.5 https://www.chemical.ai/blog/tag/Revolution+Medicines monthly 0.5 https://www.chemical.ai/blog/tag/Drug+Discovery+and+Development monthly 0.5 https://www.chemical.ai/blog/tag/BCL-2+inhibitor monthly 0.5 https://www.chemical.ai/blog/tag/elironrasib+synthesis monthly 0.5 https://www.chemical.ai/blog/tag/GLP-1+Receptor+Agonists+%28GLP-1RAs%29 monthly 0.5 https://www.chemical.ai/blog/tag/Targeted+Protein+Degradation monthly 0.5 https://www.chemical.ai/blog/tag/Macrocyclic+Drug+Synthesis monthly 0.5 https://www.chemical.ai/blog/tag/Organic+Light-Emitting+Materials monthly 0.5 https://www.chemical.ai/blog/tag/radical+cross-coupling monthly 0.5 https://www.chemical.ai/blog/tag/insecticides monthly 0.5 https://www.chemical.ai/blog/tag/synthetic+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/Process+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/BCL6+Degrader monthly 0.5 https://www.chemical.ai/blog/tag/Retrosynthesis+Optimization monthly 0.5 https://www.chemical.ai/blog/tag/Diabetes+%26+Obesity+Therapeutics monthly 0.5 https://www.chemical.ai/blog/tag/AbbVie monthly 0.5 https://www.chemical.ai/blog/tag/Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/tag/Materials+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/C%E2%80%93C+bond+formation monthly 0.5 https://www.chemical.ai/blog/tag/Medicinal+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/BMS-986458 monthly 0.5 https://www.chemical.ai/blog/tag/Balinatunfib monthly 0.5 https://www.chemical.ai/blog/tag/RCC+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/Macrocyclic+Drugs monthly 0.5 https://www.chemical.ai/blog/tag/Balinatunfib+Synthesis monthly 0.5 https://www.chemical.ai/blog/tag/single-electron+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/retrosynthetic+analysis monthly 0.5 https://www.chemical.ai/blog/tag/OLED+materials monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+pathways monthly 0.5 https://www.chemical.ai/blog/tag/Therapeutic+Modalities monthly 0.5 https://www.chemical.ai/news daily 0.75 2025-03-14 https://www.chemical.ai/news/partnership-emolecules monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741536802652-XC0ES4VQ5Q55PLWQ8O70/ChemicalAI-news-partnership-emolecules.jpg News - Chemical AI and eMolecules Enter a Strategic Partnership - eMolecules & Chemical.AI Accelerating Synthesis Planning and Simplify Compound Procurement, Together. https://www.chemical.ai/news/acceleration-consortium monthly 0.5 2025-05-16 https://www.chemical.ai/news/mcule-building-blocks-integration monthly 0.5 2025-05-16 https://www.chemical.ai/news/aragen-collaboration monthly 0.5 2025-05-16 https://www.chemical.ai/news/ntu-singapore-partnership monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741540439537-EE7COMZIZWCDBD7RJ02M/ChemicalAI-news-partnership-NTU-singapore.png News - Chemical.AI partners with NTU Singapore to advance automated and AI-powered research platform for nanomaterials - eMolecules & Chemical.AI Accelerating Synthesis Planning and Simplify Compound Procurement, Together. https://www.chemical.ai/news/carbonsilicon-ai-partnership monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6e082beb-94b3-4d09-9746-eb2a7b1c9e0b/ChemicalAI-news-partnership-CarbonSilicon-ai.png News - Chemical.AI and CarbonSilicon AI have Reached a Strategic Cooperation to Jointly Promote Drug Research and Development - eMolecules & Chemical.AI Accelerating Synthesis Planning and Simplify Compound Procurement, Together. https://www.chemical.ai/news/novalix-collaboration monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542226711-TLU67LX9C79UTIZ7JX0B/ChemicalAI-news-partnership-NovAliX.png News - Chemical.AI and NovAliX Reached A Milestone in Collaboration https://www.chemical.ai/news/chemicalai-announced-a-partnership-with-pfizer-to-create-ai-driven-pharmaceuticals monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542091333-S0J7SUH19T80I8YJ3SZ5/ChemicalAI-news-partnership-Pfizer.jpg News - Chemical.AI announced a partnership with Pfizer to create AI-driven pharmaceuticals https://www.chemical.ai/news/series-b-funding monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542253151-KK2QH5FKICGUHXOCWTLD/ChemicalAI-news-14-million-series-B-funding.png News - Chemical.AI Announces nearly $14 million Series B funding https://www.chemical.ai/news/chemaxon-collab monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542282223-RQ9MD41BBBQSWSM09QT8/ChemicalAI-news-partnership-Chemaxon.png News - Chemaxon and Chemical.AI Announce Collaboration in Scientific Informatics Software Integration https://www.chemical.ai/news/partnership-scilligence monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542305380-BN4FG33NE9M4RZZSMX56/ChemicalAI-news-partnership-Scilligence.png News - Chemical.AI and Scilligence Launched their Strategic Cooperation to Co-develop ELN-based Data Integration https://www.chemical.ai/news/series-a-funding monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542375396-2T5JQEH7HIQRBHPUWCV4/ChemicalAI-news-5-million-series-A-funding.png News - Chemical.AI Completed Series A Round of Funding of over 5 Million USD-Big Data and Artificial Intelligence Assist the Synthesis of Chemical Compounds https://www.chemical.ai/news/chemicalai-announced-a-partnership-with-pfizer-to-create-ai-driven-pharmaceuticals-2jl2f-mepwp-lyakg-m4tmd-623py-7gf78 monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542404907-UJMFHEZBQWSVHLXAY2CS/ChemicalAI-news-partnership-NovAliX-drug-discovery.png News - NovAliX Partners with Chemical.AI to Develop Artificial Intelligence Toolkit for Drug Discovery https://www.chemical.ai/home daily 1.0 2026-04-29 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511387030-5LI1E5QMVTQ2RY9S00A4/20140228_Trade+151_0046+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511440608-5BVMHVN4WR2I9YQV1WWR/Aro+Ha_0010+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511467879-K5J9BYNACHJVDV3BNSFU/Aro+Ha_0387+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511743693-J3A8OYH6X8C7RXNU5K0J/20140301_Trade+151_0124+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694644871-IC85FNH781UNZSZEGHDR/Aro+Ha_0428.jpg Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/644e0280-4e22-40c7-9d9a-9e2ee445149a/chemicalai-chemairs-synthesizability-assessment-sa-score-icon.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c6ba729e-f8e0-4940-bc69-8dedaa4ccd7f/chemicalai-partners-logos_pfizer.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/13d1f9b5-248c-40cc-962c-fd839508dced/chemicalai-partners-logos_roche.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7e4716a0-191d-4d1d-b4bf-b2a76cdf2276/chemicalai-partners-logos_l%27ore%CC%81al.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8d533def-b730-406a-9b73-3d088c140a58/chemicalai-partners-logos_wuxi-apptec.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a7d2c73a-f8a6-4b06-8e3d-081ed9819f45/chemicalai-partners-logos_pharmaron.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/22cd8165-fd32-453d-898a-83c4b437b8ce/chemicalai-partners-logos_frontier-medicines.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abcc6f3e-1421-47b4-b9b3-f6685f593584/chemicalai-partners-logos_hengrui.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b4deb101-1754-4194-99f0-ba658def0e2c/chemicalai-partners-logos_aragen.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ec62a30f-b94c-4c12-a700-62b5ad655edd/chemicalai-partners-logos_hitgen.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/90262339-d75b-45e4-81a9-c8b2a0e4ea35/chemicalai-partners-logos_novalix.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bc62002b-ad08-4aba-9399-bcd587fa40f7/chemicalai-partners-logos_agrofina.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/54252b31-9f2b-4777-b3ce-928736f71a94/chemicalai-partners-logos_mesentech.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/babad79e-05e8-4eaa-b911-e0e22cc5c621/chemical-ai-partners-logos_Genentech.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/45ad0a97-faff-4d95-821d-707c769417f8/chemical-ai-partners-logos_Paraza.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2db4355c-2e01-40f8-8496-7655d0d3dff8/chemical-ai-partners-logos_Molport.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/69d9bfac-bc17-457d-bd2b-489967220f96/chemical-ai-partners-logos_Enamine.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f3b006f6-ecf0-4794-960f-89698bb6d206/chemical-ai-partners-logos_bioduro-sundia.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6eaf722a-a74e-495c-a69c-c58bd6e51e21/chemical-ai-partners-logos_university-of-toronto.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/85effdcb-171d-4aaa-8fce-b11b97c96e6c/chemical-ai-partners-logos_superluminal-medicines.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c84f95a6-eff1-480e-9063-71ec51b891ed/20250917-085707.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/25b3a1d1-54e2-4ac2-9df6-cf894e4c373d/20250917-085714.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/75f507fc-3e8a-4297-b25d-d922d2432404/smarter-synthesis-starts-here-02.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/70698bc0-4684-42e1-8224-c03a3bde4c40/chemairs_-monitor-light-interface-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8fc842da-1d3f-4544-8bef-463d1263725b/chemairs_-monitor-light-interface-02.png https://www.chemical.ai/contact daily 0.75 2026-04-29 https://www.chemical.ai/chemairs daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/19a0459b-92df-44b5-91f9-94845ab73b3b/chemairs-impurity-prediction-tool.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3ccfdede-e6e3-4d1c-aa1c-044a12f89364/chemairs-condition-optimization.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5d9e9feb-38f4-4f97-ad76-3bf7d81b948d/chemairs-forward-synthesis.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4df06af4-ce17-4c84-9e31-5a725b816d68/chemairs-secure-eln-icon.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cd254fa6-f0c5-4919-aaf1-dc5751fab89e/chemairs-real-time-cost-icon.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f0a1a6d1-13ce-4a56-999b-ed3d4b19637e/chemairs-type-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3c3c4c22-018a-414e-a2ca-025e167e33e5/chemicalai-chemairs-retrosynthesis-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e885388e-12c1-4e31-8fe0-8eafadca9640/chemicalai-chemairs-process-chemistry-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/644e0280-4e22-40c7-9d9a-9e2ee445149a/chemicalai-chemairs-synthesizability-assessment-sa-score-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/35af0427-6547-460b-8036-a7a66c99fba2/chemairs_-monitor-dark-interface-01.png https://www.chemical.ai/about daily 0.75 2025-09-17 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/13d1f9b5-248c-40cc-962c-fd839508dced/chemicalai-partners-logos_roche.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c6ba729e-f8e0-4940-bc69-8dedaa4ccd7f/chemicalai-partners-logos_pfizer.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7e4716a0-191d-4d1d-b4bf-b2a76cdf2276/chemicalai-partners-logos_l%27ore%CC%81al.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8d533def-b730-406a-9b73-3d088c140a58/chemicalai-partners-logos_wuxi-apptec.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a7d2c73a-f8a6-4b06-8e3d-081ed9819f45/chemicalai-partners-logos_pharmaron.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/22cd8165-fd32-453d-898a-83c4b437b8ce/chemicalai-partners-logos_frontier-medicines.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abcc6f3e-1421-47b4-b9b3-f6685f593584/chemicalai-partners-logos_hengrui.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b4deb101-1754-4194-99f0-ba658def0e2c/chemicalai-partners-logos_aragen.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ec62a30f-b94c-4c12-a700-62b5ad655edd/chemicalai-partners-logos_hitgen.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/90262339-d75b-45e4-81a9-c8b2a0e4ea35/chemicalai-partners-logos_novalix.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bc62002b-ad08-4aba-9399-bcd587fa40f7/chemicalai-partners-logos_agrofina.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/54252b31-9f2b-4777-b3ce-928736f71a94/chemicalai-partners-logos_mesentech.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/babad79e-05e8-4eaa-b911-e0e22cc5c621/chemical-ai-partners-logos_Genentech.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/45ad0a97-faff-4d95-821d-707c769417f8/chemical-ai-partners-logos_Paraza.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/69d9bfac-bc17-457d-bd2b-489967220f96/chemical-ai-partners-logos_Enamine.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f3b006f6-ecf0-4794-960f-89698bb6d206/chemical-ai-partners-logos_bioduro-sundia.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/85effdcb-171d-4aaa-8fce-b11b97c96e6c/chemical-ai-partners-logos_superluminal-medicines.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fb657cf1-06ce-4a17-9c26-90d770abbbe8/20250829-125726.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/04d517c9-8756-446e-810f-9e8112f1a320/20250829-125705.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/78e32006-59dc-4050-9231-bae4ca0b71f9/20250829-125715.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f5bc106e-bcb0-46f4-9883-9da93d7030d4/20250917-085621.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/37b56b5c-c8b0-4682-b909-217530701acb/20250917-085634.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/70698bc0-4684-42e1-8224-c03a3bde4c40/chemairs_-monitor-light-interface-01.png https://www.chemical.ai/condition-optimization daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/995e352d-d7f7-41cb-b889-aa67baa2b6f2/chemairs-features-condition-optimization-hero-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d86cf887-9f9a-496c-983d-2c103a5b47f3/chemairs-feature-condition-optimization-02.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6e62c083-16d3-43c0-acc2-6849c76da090/chemairs-feature-condition-optimization-03.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4ea06350-c2ea-457a-93db-440d5b3014aa/chemairs-screen_-condition-optimize-export-data.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8fc842da-1d3f-4544-8bef-463d1263725b/chemairs_-monitor-light-interface-02.png https://www.chemical.ai/retrosynthesis daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5b225c85-3bf8-4dac-ab92-6da99782957b/chemairs-features-retrosynthesis-icon-color.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6fa4119b-01f1-4566-8cb1-f26e6f7f23b5/retrosynthesis-route-design-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/84f5c1cb-138c-4d2a-94bf-baad98b9d0ce/retrosynthesis-speed-up-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/001a6b5a-5249-4adb-a231-6fd301dee9de/retrosynthesis-building-block-data-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e300f104-651c-4115-9f73-97e7f8172eae/retrosynthesis-eln-data-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/312c142e-f28e-4bc3-9bda-0d0a472931c5/retrosynthesis-local-deployment-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5fee2827-cbe1-4bb8-b767-d09fd28869cb/chemairs_-monitor-dark-interface-02.png https://www.chemical.ai/synthesizability daily 0.75 2026-04-30 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/541be6db-35f3-4ee8-a18a-34211627eacf/chemairs-SA-score-icon-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f3c96519-54bf-4991-865c-3cb320b917fd/chemairs-sa-score-icon_reaction-logic.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e70442e2-e944-4c59-aad6-dbe427ba9a4a/chemairs-sa-score-icon_building-blocks.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/64c690d9-cb4c-4608-9e51-10e53fb9a48c/chemairs-sa-score-icon_cost.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c87c4510-15df-4ad5-94d2-aee8a6a533e5/airs-product07.jpg https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/677fb174-c67b-4347-9263-e655bbd2d644/chemairs-merck-synthesis-study-1346-molecules.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/35af0427-6547-460b-8036-a7a66c99fba2/chemairs_-monitor-dark-interface-01.png https://www.chemical.ai/impurity-prediction daily 0.75 2026-04-30 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9d363dd6-143d-47f4-8842-520ac8d97b6b/chemairs-features-impurity-prediction-icon-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4394afba-59d9-4ebe-9ab7-8021aa1b87ad/Impurity-prediction.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f5aec09a-b7b8-4762-9436-8ab8b91dab2d/chemairs-impurity-prediction-orpd.png https://www.chemical.ai/copyright daily 0.75 2025-03-10 https://www.chemical.ai/process-chemistry daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/19334bbf-0281-4028-a510-7c80acd41851/chemairs-features-process-chemistry-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0bf956e9-c3d2-45b1-97e2-38e2e265dfa0/chemairs-process-chemistry_smarter-route.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8eb95d1a-c08f-4eba-8681-d81bc04ba549/chemairs-process-chemistry_optimize-condition.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/61ae4da7-d0b3-4fbb-96f5-52a6d8945fbc/chemairs-process-chemistry_alternative-reagents.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4b12bfce-e03b-4dc3-a024-2d561e95fed6/chemairs-process-chemistry_scale-up.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b4deb101-1754-4194-99f0-ba658def0e2c/chemicalai-partners-logos_aragen.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c6ba729e-f8e0-4940-bc69-8dedaa4ccd7f/chemicalai-partners-logos_pfizer.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abcc6f3e-1421-47b4-b9b3-f6685f593584/chemicalai-partners-logos_hengrui.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/35af0427-6547-460b-8036-a7a66c99fba2/chemairs_-monitor-dark-interface-01.png https://www.chemical.ai/forward-synthesis daily 0.75 2025-03-12 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f85d202a-574b-4a47-afdb-3b1166a0b5b8/chemairs-forward-synthesis-core-analysis.png Forward Synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2c9c56da-4ad5-4bc7-ba52-c9dc251edb8e/chemairs-forward-synthesis-core-stability.png Forward Synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f4c3dd92-7c20-4ed5-9355-a7e911988624/chemairs-forward-synthesis-icon.png https://www.chemical.ai/404 daily 0.75 2025-03-07 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a0250ccd-d6ab-4e41-9171-0e4bb33875f6/chemical-ai-404-search.png https://www.chemical.ai/privacy-policy daily 0.75 2025-03-13 https://www.chemical.ai/cookie-notice daily 0.75 2025-03-09 https://www.chemical.ai/impurities-case-studies daily 0.75 2025-03-20 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/68fd245c-4a1a-4505-9195-9b1fccffdf21/Screenshot+2025-03-20+112541.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d50c4e0d-e7c8-4067-888f-3ba0c7ee193d/Screenshot+2025-03-20+114102.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ced8a4bd-de20-461f-9c24-aa0968684966/Screenshot+2025-03-20+114247.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bc31ddd3-cb89-43fd-b5ae-1172ae9c65ce/Screenshot+2025-03-20+114442.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9101824c-0319-47d6-b3bc-48bb1c28ac18/Screenshot+2025-03-20+114737.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9a07faf9-e7d8-4b72-900f-8d348d8baff3/Screenshot+2025-03-20+114813.png https://www.chemical.ai/bayesian-optimization daily 0.75 2026-01-14 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f85d202a-574b-4a47-afdb-3b1166a0b5b8/chemairs-forward-synthesis-core-analysis.png Bayesian Optimization https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2c9c56da-4ad5-4bc7-ba52-c9dc251edb8e/chemairs-forward-synthesis-core-stability.png Bayesian Optimization https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/995e352d-d7f7-41cb-b889-aa67baa2b6f2/chemairs-features-condition-optimization-hero-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4394afba-59d9-4ebe-9ab7-8021aa1b87ad/Impurity-prediction.png https://www.chemical.ai/faq-1 daily 0.75 2026-06-15